MAR | Acarix decides on a guaranteed rights issue of approximately SEK 56 million

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent
approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a
maximum of 86,156,738 shares with preferential rights for the Company's existing shareholders
(the "Rights Issue"). If fully subscribed, the Rights Issue will provide the Company with
approximately SEK 56 million before deduction of costs related to the Rights Issue.
The Company has received guarantee undertakings from external investors of approximately SEK 50.4 million,corresponding to approximately 90 percent of the Rights Issue. The amount from SEK 50.4 million
up to approximately SEK 56 million in the Rights Issue is thus not covered by guarantee
undertakings. The board of directors will today announce through a separate press release a notice
to attend the Extraordinary General Meeting, which will be held on 11 August 2020, to approve the
board of director's decision on the Rights Issue.

PR_Acarix_Guaranteed Rights Issue

PR_Acarix_Garanterad Företrädesemission


About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.